What would be your second line approach for a patient with MSI-H metastatic colon cancer who progressed on first line chemotherapy?
Would you switch chemotherapy regimens (i.e if the patient received FOLFOX/Avastin, change to FOLFIRI/Avastin)? Would you treat wuth immunotherapy per the latest data from Checkmate 142?
1 Answer
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
I would definitely favor nivolumab + ipilimumab in this setting. Although we don't have a randomized comparison, the response rate, duration of response, and PFS reported in CheckMate 142 clearly exceed what we would expect with second-line chemotherapy. This is even more remarkable when you conside...
Join for free or sign in to see the full answer